Mrs. Kara Marie Turnbull, PA-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 50 Macedonia Church Rd, Taylorsville, NC 28681 Phone: 828-635-8430 Fax: 828-874-0833 |
Lauren Hall, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 338 1st Ave Sw Ste 1, Taylorsville, NC 28681 Phone: 828-632-9704 |
Mr. Jeffrey A Katz, P.A. Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1668 N C Highway 16 South, Taylorsville, NC 28681 Phone: 828-632-9736 Fax: 828-632-9544 |
Andrew C Pyle, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 60 2nd Ave Sw, Taylorsville, NC 28681 Phone: 828-270-3604 Fax: 828-352-9607 |
Ashley Moore Stell, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1668 Nc Highway 16 S, Taylorsville, NC 28681 Phone: 828-635-3149 |
Tonya Meadows Millsaps, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 393 3rd Ave Sw, Taylorsville, NC 28681 Phone: 704-871-2163 |
Mr. David Charles Baker, PA-C Physician Assistant - Medical Medicare: Not Enrolled in Medicare Practice Location: 633 Old Landfill Rd, Taylorsville, NC 28681 Phone: 828-632-1331 Fax: 828-632-1346 |
News Archive
Human tissues normally discarded after surgical procedures could be a rich additional source of stem cells for regenerative medicine. New research from BioMed Central's open access Journal of Translational Medicine shows for the first time that human fallopian tubes are abundant in mesenchymal stem cells which have the potential of becoming a variety of cell types.
Bedfont, is a small family-run business that specialises in the design and manufacture of breath and gas analysis monitors for medical application.
The bio-pharmaceutical marketplace - and the Oncology therapeutic area in particular - continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new Oncology products are scrutinizing their strategies and tactics to support market education.
An innovative vaccine therapy developed at Roswell Park Cancer Institute is being tested in a multisite clinical trial involving 50 patients with newly diagnosed glioblastoma brain tumors. The phase II study, now accruing patients at both Roswell Park and the Cleveland Clinic, will assess the effectiveness of the SurVaxM vaccine in combination with standard chemotherapy as treatment for this often-fatal cancer.
› Verified 3 days ago